Ballester Frederic, Gabaldó-Barrios Xavier, Jiménez-Franco Andrea, Pujol Isabel, Iftimie Simona, Camps Jordi, Parra Sandra, Castro Antoni, Joven Jorge
Department of Clinical Laboratory, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, Catalonia, 43204, Reus, Spain.
Department of Clinical Laboratory, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, Catalonia, 43204, Reus, Spain; Autoimmunity, Infection and Thrombosis Research Group (GRAIIT), Department of Internal Medicine, Hospital Universitari de Sant Joan, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Av. Dr. Josep Laporte 2, Catalonia, 43204, Reus, Spain.
Chem Biol Interact. 2025 Sep 5;418:111606. doi: 10.1016/j.cbi.2025.111606. Epub 2025 Jun 12.
Community-acquired pneumonia (CAP) remains a major health concern, with oxidative stress and inflammation playing key roles in its pathophysiology. This study examines the potential of paraoxonase-1 (PON1)-related variables as biomarkers for diagnosing and managing CAP. A prospective case-control study included 78 patients with community-acquired pneumonia (CAP) who were hospitalized and 80 healthy controls. Serum PON1 concentration (PON1c), PON1 arylesterase (ARE) and paraoxonase (PARX) activities, and inflammatory markers (C-reactive protein, procalcitonin, and C-C motif chemokine ligand 2 were measured and compared with lipid profiles and clinical severity scores. Receiver operating characteristic curve analysis was used to assess their diagnostic and prognostic value. CAP patients exhibited significantly lower ARE and PARX activities but higher PON1c levels than controls, with these changes correlating with increased inflammatory markers and decreased total and high-density lipoprotein cholesterol concentrations. PON1-related variables demonstrated strong diagnostic accuracies (areas under the curve >0.90), outperforming traditional inflammatory markers. However, although these variables provided insights into disease severity and pathophysiology, their prognostic value and ability to differentiate microbial etiologies were limited. These findings suggest that PON1-related variables may serve as promising diagnostic biomarkers for CAP, but their role in prognosis and guiding antimicrobial therapy requires further investigation. Future studies should validate these results in larger and more diverse populations while exploring the mechanistic involvement of PON1 in CAP progression.
社区获得性肺炎(CAP)仍然是一个主要的健康问题,氧化应激和炎症在其病理生理学中起关键作用。本研究探讨对氧磷酶-1(PON1)相关变量作为诊断和管理CAP生物标志物的潜力。一项前瞻性病例对照研究纳入了78例住院的社区获得性肺炎(CAP)患者和80名健康对照者。测量血清PON1浓度(PON1c)、PON1芳基酯酶(ARE)和对氧磷酶(PARX)活性以及炎症标志物(C反应蛋白、降钙素原和C-C基序趋化因子配体2),并与血脂谱和临床严重程度评分进行比较。采用受试者工作特征曲线分析评估其诊断和预后价值。与对照组相比,CAP患者的ARE和PARX活性显著降低,但PON1c水平升高,这些变化与炎症标志物增加以及总胆固醇和高密度脂蛋白胆固醇浓度降低相关。PON1相关变量显示出较强的诊断准确性(曲线下面积>0.90),优于传统炎症标志物。然而,尽管这些变量为疾病严重程度和病理生理学提供了见解,但其预后价值和区分微生物病因的能力有限。这些发现表明,PON1相关变量可能是有前景的CAP诊断生物标志物,但其在预后和指导抗菌治疗中的作用需要进一步研究。未来的研究应在更大、更多样化的人群中验证这些结果,同时探索PON1在CAP进展中的机制参与情况。